Nephros (NEPH) Liabilities and Shareholders Equity (2010 - 2026)

Nephros' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $13.8 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 17.12% year-over-year to $13.8 million; the TTM figure through Mar 2026 stood at $52.9 million (up 19.0% YoY), while the FY2025 annual figure was $13.6 million, up 21.69% from the prior year.
• Liabilities and Shareholders Equity was $13.8 million for Q1 2026 at Nephros, up from $13.6 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $15.5 million in Q1 2022 to a low of $10.4 million in Q2 2023.
• Historically, Liabilities and Shareholders Equity has averaged $12.1 million across 5 years, with a median of $11.4 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity tumbled 37.68% in 2022, then rose 27.55% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $11.0 million in 2022, then climbed by 7.84% to $11.9 million in 2023, then retreated by 5.49% to $11.2 million in 2024, then advanced by 21.69% to $13.6 million in 2025, then climbed by 1.12% to $13.8 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $13.8 million (Q1 2026), $13.6 million (Q4 2025), and $13.2 million (Q3 2025), per Business Quant data.